Charles River is pleased to announce that our 2015 Research Models and Services catalog is now available electronically.
Charles River has broadened its comprehensive CNS disease modeling platform with the addition of pharmacological MRI (phMRI). This powerful tool complements traditional imaging to accelerate the development of drugs that target neurological disorders.
Charles River has partnered with ProTrials Research to help you develop nonclinical testing programs that transition with ease into the human trial phase of drug development.
In addition to the traditional in vitro neutralization assays based on primary HUVEC endothelial cells, Charles River now offers the more cost-effective, robust and validatable VEGF reporter assay to illustrate the in vivo mechanism of action of bevacizumab and its follow-on biologics during the early phase of drug development.
For historical reasons, parathyroid hormone (PTH) bioactivity is mainly determined by tedious and time-consuming cAMP ELISA assays. The newly established homogenous time-resolved fluorescence (HTRF) cAMP assay is an attractive alternative, enabling researchers to receive reliable PTH bioactivity data with improved assay robustness and validatability.
Charles River has acquired ChanTest, a market leader in ion channel drug discovery and associated in vitro safety testing. The addition of this world-class organization to our Discovery Services portfolio complements our existing ion channel capabilities and broadens our scientific depth and the services we can provide to our clients in their mission to discover and develop new medicines.
In vitro antibody-dependent cellular phagocytosis (ADCP) assays based on primary macrophages as effector cells are excellent tools to illustrate the in vivo mechanism of action (MOA) of a therapeutic monoclonal antibody (mAb) during the early phase of drug development.
Charles River offers an integrated approach for the development of biosimilars, including regulatory consultation, testing and characterization, nonclinical studies and clinical sample analysis.
Multiplex assays offer several advantages that make them a sought after technology to increase efficiency in the lab and get the most information out of each sample taken. Charles River has validated several biomarker multiplexed assays and is in the process of qualifying and validating more.
ICH guidelines require the use of two species in nonclinical studies for pharmaceuticals; one rodent and one nonrodent species. With many anatomical, physiological and functional similarities to humans, the miniature pig (minipig, Sus scrofa) has become a viable alternative nonrodent animal model in nonclinical safety testing.